Given the critical requirement for tumor-infiltrating functional CTLs in durable immunity, our data provide rationale for combining alternative NF-κB modulation with immunotherapies to promote positive secondary immune effects, increase the influx of antitumor immune cells into the TME, and improve the durability of these responses. This evidence concerns the gene NFKB1 and neoplasm.